MCM7 and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma (PDAC) [46], liver [45], breast [47], and colon cancers [46], MCM7 was shown to influence therapeutic response, supporting its promise as a potential therapeutic target.